Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy
TheFly reported that QNCX presented Phase 2a clinical results for LAM-001 on May 18, at the American Thoracic Society conference in Orlando, evaluating an inhaled rapamycin formulation for pulmonary arterial...



